YAP1 and renal carcinoma: High levels of nuclear YAP/TAZ expression are associated with aggressive tumor phenotypes, therapy resistance, and poor clinical outcomes in various cancers, including lung, breast, ovarian, liver, and renal cancer (Gupta et al., 2023[40], Yang et al., 2024[164]).